Preamble
The ESC guidelines help physicians to make decisions in their practice, but do not override the responsibility of health professionals to make decisions and to follow the rules and regulations applicable to drugs and devices. The level of evidence and the strength of recommendation are outlined in Tables 1 and 2 . The Czech Society of Cardiology endorses ESC guidelines and prepares condensed summaries (text o5000 words plus selected tables and figures) from the original full text.
For details and for references see the original ESC document [1] .
Introduction

Definition of acute myocardial infarction
Acute myocardial infarction is defined as the evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Criteria are described in Table 3 . Most STEMI patients show a typical rise in biomarkers and progress to Q-wave infarction.
Epidemiology of ST-segment elevation myocardial infarction
Coronary artery disease accounts for 12.8% of all deaths. The incidence of hospital admission for STEMI in Sweden is 66 STEMI/100,000/year, similar figures were reported in the Czech Republic, Belgium and USA.
STEMI mortality is influenced mainly by age and Killip class, other factors being time delay to treatment, mode of treatment, prior myocardial infarction, diabetes, renal failure, number of stenosed coronary arteries, ejection fraction. The in-hospital mortality of unselected STEMI patients varies between 6% and 14%.
3.
Emergency care
Initial diagnosis
A working diagnosis of STEMI is based on chest pain lasting Z20 min, not responding to nitroglycerine. Important clues are a history of CAD and pain radiation to the neck, lower jaw or left arm. Some patients (more likely women, diabetic or elderly) have atypical symptoms: nausea/vomiting, dyspnoea, fatigue, palpitations, syncope. Timely diagnosis of STEMI is crucial (Table 4) . A 12-lead ECG should be obtained at first medical contact (FMC). STsegment elevations (STE) should be found in two contiguous leads and be Z0.25 mV in men r40 years, 0.2 mV in men 440 years, or Z0.15 mV in women in leads V2-V3; and/or Z0.1 mV in other leads (in the absence of LV hypertrophy or LBBB). In inferior STEMI it is advisable to record right precordial leads (V3R and V4R-concomitant right ventricular infarction). Isolated posterior myocardial infarction (ST segment depression Z0.05 mV in leads V1-V3) should be treated as a STEMI. The use of posterior leads (STE in V7-V9 Z0.05 mV (Z0.1 mV in men o40 years) is recommended.
In patients with clinical suspicion of on-going myocardial ischemia with new or presumed new LBBB, immediate reperfusion therapy is indicated. Prompt management should be also considered when persistent ischaemic symptoms occur in the presence of RBBB.
Ventricular pacing may prevent interpretation of ECG. Reprogramming the pacemaker may be considered in patients not dependent on ventricular pacing. c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 7 3 -e 2 8 9 e275
Patients without diagnostic ECG. It is important to repeat the ECG (monitor ST segment). On-going suspicion of myocardial ischemia is an indication for emergency coronary angiography (Table 5) Left main coronary obstruction. The presence of ST depression 40.1 mV in Z8 surface leads coupled with STE in aVR and/or V1 suggests ischemia due to multivessel or left main coronary artery obstruction.
3.2.
Relief of pain, breathlessness and anxiety (Table 6 
3.4.
Pre-hospital logistics of care
Delays
The most critical time is the very early phase (risk of cardiac arrest). A defibrillator must be made available as soon as c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 7 3 -e 2 8 9 e276
possible. The early reperfusion is critical for myocardial salvage. The treatment delays are index of quality of care; they should be recorded in every hospital providing care to STEMI patients.
There are several components of delay in STEMI ( Fig. 1 
):
Patient delay is the delay between symptom onset and FMC. To minimize patient delay, the public should be aware of symptoms of acute myocardial infarction and call to emergency services. It may be wise to provide stable CAD patients with a copy of their routine baseline ECG for comparison purposes by medical personnel.
Delay between FMC and ECG diagnosis should be o10 min.
Delay between FMC and reperfusion therapy is a predictor of outcomes. The goal should be FMC to wire passage into the culprit artery time r90 min (r60 min in high-risk cases with large anterior infarcts presenting within o2 hs). If reperfusion therapy is fibrinolysis, a goal is FMC to needle time r30 min. In PCI-capable hospitals, the goal is a 'door-toballoon' delay r60 min.
Delay between symptom onset and reperfusion therapy is most important, since it reflects total ischaemic time. It should be reduced as much as possible.
Emergency medical system
A well-trained EMS and a shared written STEMI management protocol are critically important. Pre-hospital diagnosis, triage and initial emergency treatment in the ambulance 
has been shown to be associated with greater use of reperfusion therapies, reduced delays and improved clinical outcomes. All ambulance personnel should be trained to recognize acute myocardial infarction, administer oxygen, relieve pain and provide basic life support. All emergency ambulances should be equipped with ECG recorders, defibrillators and at least one person on board trained in advanced life support. Ambulance staff should be able to record an ECG for diagnostic purposes and either interpret it or transmit it to a coronary care unit.
Networks
Optimal STEMI treatment should be based on networks between hospitals with various levels of technology, connected by an efficient ambulance service. Cardiologists should actively collaborate with emergency physicians. The main features of such a network are:
Definition of geographical areas of responsibility; Shared management protocols; Pre-hospital triage to the appropriate institutions, bypassing non-PCI hospitals whenever primary PCI can be implemented;
At the PCI hospital the patient should immediately be taken to the catheterization laboratory, bypassing the emergency department or coronary care unit;
Patients presenting to a non-PCI-capable hospital should be immediately transported for primary PCI;
If ambulance with a STEMI patient arrives at a non-PCIcapable hospital, the ambulance should await the diagnosis and if STEMI is confirmed should continue to a PCIcapable hospital.
Primary PCI centres should perform the procedure systematically on a 24/7 basis for all STEMI patients. The population catchment area for network systems in European countries offering primary PCI to the majority of their population is 0.3-1.0 million. In small service areas the experience may be suboptimal due to an insufficient number of STEMI patients.
General practitioners
Consultation with a general practitioner (instead of a direct call to the EMS) increases pre-hospital delay. Therefore, in general, the public should be educated to call the EMS, rather than the primary care physician, for symptoms suggestive of myocardial infarction.
Admission procedures
Candidates for primary PCI should be admitted directly to the catheterization laboratory, bypassing the emergency department and/or intensive coronary care unit. Patients who are candidates for fibrinolysis should be treated directly in the pre-hospital setting.
Logistics
The patient should call central EMS number as soon as possible after the onset of chest pain (Fig. 2) . EMS dispatches a fully equipped ambulance with personnel trained to interpret 12-lead ECG. Once the ECG reveals ST-segment elevation (or new or presumed new BBB), the nearest PCI hospital is informed about the expected time of patient arrival. During the ambulance transfer, the catheterization laboratory (incl. staff) is prepared, allowing direct transfer of the patient to the catheterization laboratory table. When the diagnostic ECG Table 8 -Logistics of pre-hospital care.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 7 3 -e 2 8 9 has been done elsewhere (not by the EMS), the EMS is called for transfer and the above chain follows (Table 8) .
3.5.
Reperfusion therapy
Restoring coronary flow and myocardial tissue reperfusion
For patients with STEMI (or new or presumed new BBB)within 12 h of symptom onset, early reperfusion should be performed as early as possible (Table 9 ).Reperfusion therapy should be considered if there is clinical and/or electrocardiographic evidence of on-going ischemia, even if symptoms started 412 h before or when the pain and ECG changes have been stuttering. There is no consensus whether PCI is beneficial 412 h from symptom onset in the absence of clinical and/or electrocardiographic evidence of on-going ischemia. One small randomized study has shown myocardial salvage and improved 4-year survival from primary PCI when performed 12-48 h after symptom onset. The OAT trial found no benefit of routine coronary intervention when performed 3-28 days after acute myocardial infarction.
Selection of a strategy for reperfusion
Primary PCI is the preferred reperfusion strategy in STEMI when performed within guideline mandated times by an experienced team (Fig. 1) . From any FMC location the transfer via EMS to the PCI centre should be implemented immediately. Hospitals with non-stop (24/7) PCI availability should use primary PCI as a routine treatment. Randomized trials have shown repeatedly that primary PCI is superior to hospital fibrinolysis. If primary PCI cannot be performed within 120 min of FMC by an experienced team, fibrinolysis should be considered, particularly if it can be given prehospital and within the first 120 min of symptom onset (Fig. 2 ). It should be followed by rescue PCI or early routine angiography.
Long delays to primary PCI are associated with worse clinical outcomes. The 'PCI-related delay' is the difference between FMC to balloon inflation minus FMC to start of fibrinolytic therapy. In the US registry, the mean PCI-related time delay where mortality rates of the two reperfusion strategies were comparable was calculated at 114 min.
Primary PCI should be performed within 90 min after FMC in all cases (o60 min in patients presenting directly to PCI centre). In early presenters with large myocardium at risk, the delay should be o60 min. These target delays for primary PCI are quality indicators and they differ from the maximal PCIrelated delay of 120 min, which is useful in selecting primary PCI over immediate thrombolysis as the preferred mode of reperfusion (Table 10) .
3.5.3. Primary percutaneous coronary intervention 3.5.3.1. Procedural aspects of primary PCI. (Table 11 ) Only the infarct-related artery should be treated during the initial intervention. The only exception is cardiogenic shock with multiple critical (Z90% or angiographically unstable) lesions if ischemia persists after PCI of the culprit lesion. The radial approach reduced the incidence of bleeding events in ACS. Reduced mortality in STEMI was observed with radial approach in the RIVAL and RIFLE-ACS trials. However the results suggested that the benefit of radial access depends upon the radial expertise of operators. In primary PCI, drug-eluting stents (DES) reduce the risk of repeat revascularization without influencing the risk of death, myocardial infarction or stent thrombosis on long term follow up. 
The routine use of manual thrombus aspiration in the TAPAS trial reduced one-year mortality. Mechanical thrombectomy or embolic protection devices have not been found to provide similar benefits. Several large randomized trials are currently running to confirm the results of TAPAS. The presence of residual thrombus and/or spasm can lead to stent under-sizing (or otherwise suboptimal deployment), which is a frequent cause for restenosis or stent thrombosis in real-life practice. Intracoronary nitrates should be used before the angiographic sequence used for stent size selection.
3.5.3.2. Periprocedural pharmacotherapy. (Tables 12 and 13) Patients undergoing primary PCI should receive three antithrombotic drugs (aspirin, ADP-receptor blocker, anticoagulant) as early as possible before angiography.
Aspirin should preferably be given orally (150-300 mg, chewing) to ensure complete inhibition of TXA2-dependent platelet aggregation, but may be given intravenously (80-150 mg) in patients unable to swallow. The preferred ADP-receptor blockers are prasugrel (60 mg loading dose, 1 Â 10 mg maintenance dose) or ticagrelor 
(180 mg loading dose, 2 Â 90 mg maintenance dose). Prasugrel is contraindicated in patients with prior stroke/transient ischaemic attack and not recommended in patients Z75 years or with body weight o60 kg. The European label suggests in these patients a maintenance dose of 5 mg. Ticagrelor may cause transient dyspnoea not associated with lung abnormalities and rarely leading to discontinuation. Ticagrelor may cause asymptomatic bradycardia in the first week of therapy. Neither prasugrel nor ticagrelor should be used after previous haemorrhagic stroke and in liver disease. When these agents are not available or if contraindicated, clopidogrel 600 mg should be given, followed by 150 mg maintenance dose in the first week and 75 mg thereafter. Anticoagulants for primary PCI include UFH, enoxaparin or bivalirudin. UFH iv. bolus should be 70-100 U/kg when no GPIIb/IIIa inhibitor is planned. There are no solid data to recommend the use of ACT to tailor UFH dose. When enoxaparin is used, iv. bolus 0.5 mg/kg should be followed by s.c. treatment. Based on the ATOLL trial and on the considerable clinical experience with enoxaparin in other PCI settings, enoxaparin may be preferred over UFH. One trial demonstrated the superiority of bivalirudin over the combination of UFHþGP IIb/IIIa inhibitor, a benefit driven by a marked reduction in bleeding, associated with an initial increase in stent thrombosis.
Trials performed before the DAPT era documented benefits of GPIIb/IIIa inhibitors during primary PCI. The FINESSE trial found that routine upstream abciximab before primary PCI did not yield clinical benefit but increased bleeding risk. The BRAVE-3 trial did not show benefit from abciximab in primary PCI among patients pre-treated with 600 mg of clopidogrel. Therefore, the current role of routine GPIIb/IIIa inhibitors in primary PCI in the era of potent DAPT is questionable. Bailout use of GPIIb/IIIa inhibitors with angiographic evidence of large thrombus, slow or no-reflow and other thrombotic complications is reasonable. The AIDA-4 trial found no clinical benefit (but also no harm) with intracoronary route of administration. Therefore, the iv. route remains the standard of care for administration of GPIIb/IIIa inhibitors. Routine post-procedural anticoagulant therapy is not indicated after primary PCI except when there is a separate indication for either full-dose anticoagulation due to, for instance, atrial fibrillation, mechanical valves, LV thrombus, or prophylactic doses for prevention of venous thromboembolism in patients requiring prolonged bed rest.
3.5.3.3. Prevention and treatment of microvascular obstruction and no reflow.. Inadequate myocardial perfusion after successful opening of the infarct related artery is referred to as 'no-reflow'. The diagnosis of no-reflow: post-procedural TIMI flow o3 or myocardial blush grade 0-1 or ST resolution within 4 h of the procedure o70%.There is no evidence that intracoronary vasodilators, iv. adenosine or abciximab affect clinical outcomes in this setting. The best therapy appears to be prevention of distal embolization by manual thrombus aspiration.
Fibrinolysis and subsequent interventions
Due to the fact, that since 2002 thrombolysis for STEMI was completely replaced by primary PCI in the Czech Republic, this summary does not cover fibrinolysis and the readers are advised to read the original ESC full text document for a comprehensive information about this treatment strategy.
Revascularization strategy for STEMI with multivessel disease
It is discouraged to perform PCI of non-culprit vessels in the acute setting (exceptions: cardiogenic shock, continuous ischemia). The best strategy for STEMI patients with multivessel disease after primary PCI of the infarct-related artery is c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 7 3 -e 2 8 9 e281 not well established. Two frequently used strategies are a conservative approach (medical therapy after primary PCI and another revascularization only with evidence of ischemia) or a staged revascularization approach (PCI or CABG several days or weeks after primary PCI). Heart team decision and appropriate informed consent is needed.
Coronary bypass surgery and multivessel coronary revascularization
The need for CABG in the acute phase of STEMI is rare. CABG may be indicated in patients with patent infarct artery and anatomy unsuitable for PCI (patency of this artery provides time for surgery) or at the time of repair for patients with mechanical complications. Withholding ADP inhibitors for surgery. It is reasonable to stop clopidogrel Z5 day before surgery, to stop prasugrel Z7 day before surgery; ticagrelor may be discontinued Z4 day before surgery. It is reasonable to restart DAPT after CABG as soon as considered safe in relation to bleeding risk.
Non-reperfused patients.
When reperfusion therapy was not given, aspirin, clopidogrel and anticoagulant (UFH, enoxaparin or fondaparinux) should be given as soon as possible. Recommended doses are given in Table 13 .
Late PCI of an occluded infarct-related artery after myocardial infarction in stable patients has no benefit over optimal medical therapy. Thus, in patients presenting days after the acute event with a completed myocardial infarction, only those with recurrent angina or documented residual ischemia and proven viability on non-invasive imaging in a large myocardial territory may be considered for revascularization when the infarct artery is occluded.
3.6.
Management of hyperglycaemia in the acute phase of STEMI Hyperglycaemia on admission in ACS patients is common and is a predictor of mortality and in-hospital complications both in diabetic and non-diabetic patients. Hyperglycaemia predicts short-term prognosis (larger infarct size), whereas elevated HbA1c is associated with long-term outcome. The benefits of tight glucose control through i.v. insulin are not established. Therefore, a 'strict, but not too strict' glucose control in STEMI is reasonable (Table 14) .
4.
Management during hospitalization and at discharge 4.1.
Coronary care unit logistics and monitoring (Table 15 ) STEMI patients should be admitted to an intensive cardiac care or coronary care unit (full description in ESC c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 7 3 -e 2 8 9 position paper), or equivalent monitored unit following reperfusion treatment. ECG monitoring for arrhythmias and ST-segment deviations should be continued for at least 24 h after symptom onset in all STEMI patients. Further monitoring depends upon perceived risk.
Patients with significant LV damage should rest in bed before a first assessment of infarct extent and severity is possible for detection of early heart failure and arrhythmias. In uncomplicated cases, the patient can sit out of bed on the first day. Ambulation can often start early (particularly in patients treated via the radial access).
The optimal length of stay in the coronary care unit and hospital should be determined individually. PAMI-II trial showed that low-risk patients (aged o70 years, LV ejection fraction 445%, one-or two-vessel disease, successful PCI and no persistent arrhythmias) could be discharged from hospital at day 3. Nevertheless, early post-discharge consultations should be offered.
4.2.
Risk assessment and imaging (Table 16 ) Clinical indicators of high risk include older age, fast heart rate, hypotension, Killip class 4I, anterior infarction, previous infarction, elevated initial serum creatinine and history of heart failure. All patients should have measured the complete lipid profile, plasma glucose and renal function at the index admission. LV function and the risk of ischemia should be known before discharge. Additional arrhytmologic investigation is indicated in selected patients.
Assessment of myocardial viability
LV myocardial dysfunction may be due to necrosis (nonviable), stunning or hibernation (viable) or to their combination. Positron emission tomography, single-photon emission computed tomography, dobutamine stress echocardiography or magnetic resonance imaging might be used for detection of viable myocardium and indication for revascularisation.
Long-term therapies for ST-segment elevation myocardial infarction
Long-term management should be initiated during hospital stay and continued in collaboration with primary care physicians (Table 17) .
Lifestyle interventions and risk factor control
Key lifestyle interventions include smoking cessation and tight blood pressure control, advice regarding diet and weight control, and the encouragement of physical activity.
Smoking cessation is potentially the most effective of all secondary prevention measures and a cessation protocol should be adopted by each hospital with continued support during rehabilitation.
Diet and weight control-wide variety of foods is recommended with adjustment of calorie intake, increased consumption of fruit, vegetables, wholegrain cereals and bread, fish, lean meat, low-fat dairy products, monounsaturated and polyunsaturated fats; reduction of total fats and salt intake if blood pressure is raised. Weight reduction is needed in patients with body-mass index Z30 kg/m 2 and/or waist circumference in males/females above 102/88 cm. Physical activity-exercise therapy (thirty minutes five times per week) can reduce the anxiety, improves patient self-confidence, endothelial function and collateralization and reduces progression of coronary lesions and thrombogenic risk.
Blood pressure control-in hypertensive patients, blood pressure should be well controlled (systolic o140 mmHg but not o110 mmHg.).
Psychosocial factor interventions-at least in elderly there is evidence that stress management is useful with a strong dose-response effect between attendance rate in the group sessions and outcome rate Exercise-based rehabilitation programme-in the modern era exercise-based rehabilitation might reduce some clinical outcomes, particularly re-infarction, and global cardiovascular risk.
Resumption of activities-decisions should be individualized based on left ventricular function, completeness of revascularization and rhythm control. Table 17 -Routine therapies in the acute, subacute and long term phase of STEMI.
ACE ¼angiotensin-converting enzyme; ACS ¼acute coronary syndrom; ARB ¼angiotensin receptor blocker; BMS¼ bare metal stent; DAPT ¼ dual antiplatelet therapy; DES¼ drug-eluting stent; LDL ¼low-density lipoprotein; LV ¼left ventricular; STEMI ¼ ST-segment elevation myocardial infarction. Table 18 -Treatment of heart failure and LV dysfunction.
ACE ¼ angiotensin-converting enzyme; ARB ¼angiotensin receptor blocker; CABG¼ coronary artery bypass graft; i.v. ¼intravenous; LV ¼ left ventricular; LVEF¼left ventricular ejection fraction; PCI ¼percutaneous coronary intervention. 
Antithrombotic therapy
Aspirin-low doses (70-100 mg) are generally used indefinitely. Patients with history of hypersensitivity to aspirin can undergo desensitization, patients who are truly intolerant to aspirin can receive clopidogrel (75 mg/day).
Duration of DAPT and antithrombotic combination therapies after STEMI-dual antiplatelet therapy combining aspirin and an ADP-receptor blocker (clopidogrel, prasugrel or ticagrelor) is recommended in all patients for up to 12 months and needs to avoid premature discontinuation.
In patients with STEMI, atrial fibrillation and the need for permanent anticoagulation after primary PCI 'triple therapy' is recommended. Selection of BMS over DES would minimize its duration but should be weighed against the benefits of DES in preventing restenosis.
Preferably proton pump inhibitor gastric protection should be considered for patients with a history of gastrointestinal bleeding, and is appropriate for patients with multiple risk factors for bleeding.
The role of novel anticoagulants in combination with DAPT in secondary prevention of STEMI remains debated (higher clinical efficacy and serious bleeding in low-dose of rivaroxaban added to aspirin and clopidogrel in ATLAS ACS 2-TIMI 51; no benefit of apixaban in the APPRAISE-2 trial and dosedependent increases in major bleeding without benefit of darexaban and dabigatran).
Beta-blockers
Early oral administration of beta-blockers appears associated with benefit, but early i.v. use of beta-blockers is contraindicated in patients with clinical signs of hypotension or congestive heart failure.
Lipid-lowering therapy
High-dose statins (strongest data are for atorvastatin, 80 mg daily) should be given to all patients with acute myocardial infarction, started early. The use of lower intensity statin therapy should be considered in patients at increased risk of side-effects. Lipids should be re-evaluated after 4-6 weeks with an LDL-cholesterol concentration of o1.8 mmol/L as the goal. In patients intolerant of any dose of statin, ezetimibe should be considered.
Nitrates
Nitrates, valuable anti-anginal agents, are not routinely recommended (intravenous may be useful in hypertensive or heart failure patients without contraindications).
Calcium antagonists
Not indicated in the acute phase. In the chronic phase and contraindications to beta-blockers, verapamil may be helpful (dihydropyridines only for hypertension or angina).
4.4.7. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers ACE inhibitors (alternatively valsartan 160 mg twice daily) should be given to patients with an ejection fraction o40% or who have experienced heart failure in the early phase (not considered as mandatory in all post-STEMI patients except with diabetes). Patients who do not tolerate an ACE inhibitor should be given an ARB.
Aldosterone antagonists
Aldosterone blockade may be considered for post-STEMI patients with an ejection fraction o40%, heart failure or diabetes (serum creatinine in males/females o221/o177 mmol/L, potassium o5.0 mEq/L). Routine monitoring of serum potassium is warranted.
Magnesium, glucose-insulin-potassium, lidocaine
No benefit to the routine administration. Recommended doses of antiarrhythmic agents are given in guidelines for management of patients with atrial fibrillation(2 5 0). CCB ¼calcium-channel blocker; i.v. ¼intravenous; LoA ¼level of evidence; LV ¼left ventricular. a Calcium antagonists should be used cautiously or avoided in patients with heart failure because of their negative inotropic effects. 
Complications following ST-segment elevation myocardial infarction 5.1.
Haemodynamic disturbances: Heart failure and shock (Table 18 ) Rapid improvement in ventricular function is usually seen following early revascularization. However, if the STEMI results in transmural injury and/or microvascular obstruction, pump failure with pathological remodelling and heart failure (HF) may complicate the acute phase and result in chronic HF. LV dysfunction is the single strongest predictor of mortality following STEMI. The degree of HF is categorized according to the Killip classification. Cardiogenic shock (CS) complicates 6-10% of STEMI with hospital mortality around 50%. General measures include: thorough history, physical examination and haemodynamic assessment (ECG, blood pressure and oxygen saturation monitoring, hourly urinary output). Chest X-ray assesses pulmonary congestion. Echocardiography is crucial for the assessment of LV function and volumes, valvular function, RV function and mechanical complications detection. Deterioration of the patient's clinical status with haemodynamic compromise should trigger a re-evaluation with a repeat echocardiography. In patients with on-going ischemia, persistent ST elevation or new LBBB, the need for further revascularization should be considered. Recommended doses of antiarrhythmic agents are given in the guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. AV ¼atrioventricular; i.v. ¼intravenous; ICD ¼implantable cardioverter defibrillator; LVEF ¼left ventricular ejection fraction; VF ¼ventricular fibrillation; VT ¼ ventricular tachycardia. c QT-prolonging agents should not be used if baseline QT is prolonged. d Intravenous sotalol or other beta-blockers should not be given if ejection fraction is low.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 7 3 -e 2 8 9 5.1.1. Moderate heart failure with pulmonary oedema (Killip class III).
Non-invasive ventilation is often effective. If not, endotracheal intubation is indicated. Systolic arterial blood pressure (BP) determines the choice of inotropic or vasopressor agent. In patients with BP 490 mmHg dobutamine or levosimendan are given. Noradrenaline may be preferable in patients with hypotension and signs of CS or septicaemia. Ultrafiltration to reduce fluid overload refractory to diuretics may be useful.
5.1.2. Severe heart failure with cardiogenic shock (Killip class IV)
Management of CS complicating STEMI includes haemodynamic stability achieved with medical or mechanical circulatory support and emergent revascularization (PCI or CABG). Early revascularization improves long-term survival. It is essential to detect alternative causes of hypotension (hypovolemia, drugs, arrhythmias, tamponade, mechanical complications or RV infarction).
Antithrombotics are given as in other STEMI patients; although clopidogrel, prasugrel or ticagrelor should be deferred until angiography (immediate CABG may be necessary).
Vasopressors and inotropes are used due to favourable haemodynamic effects despite their possible deleterious cellular effects. (Table 18 ) IABP is the most widely used mechanical support. Conflicting evidence with respect to the benefit of IABP in CS is related to the difficulty of performing randomized trials in CS. Percutaneous LV assist device may be considered in patients not responding to standard therapy including inotropes, fluids and IABP.
5.2.
Arrhythmias and conduction disturbances in the acute phase are common. Arrhythmias after the early reperfusion period may be a manifestation of continuing myocardial ischemia, pump failure, altered autonomic tone, hypoxia, electrolyte and acid-base disturbances.
Atrial fibrillation (AF) is frequently associated with severe LV damage. Table 19 summarizes the treatment. Because AF will generally require anticoagulation, the benefits of DES on restenosis should be weighed against the bleeding risks (prolonged antiplatelet and anticoagulant therapy, for details see guidelines on the management of AF) Ventricular arrhythmias (Table 20 ) Ventricular tachycardia should be differentiated from accelerated idioventricular rhythm (o120 beats/min). Runs of non-sustained VT not necessarily require treatment. Electrical cardioversion is indicated if any VT persists and always if the patient is haemodynamically unstable.
Ventricular fibrillation: immediate defibrillation should be performed according to international guidelines. Indications for ICD implantation are summarized in Table 20 .
Sinus bradycardia and heart block (Table 20 ) First-degree heart block needs no treatment.Second-degree Type I (Mobitz I or Wenckebach) AV block or sinus bradycardia.
In hemodynamically unstable patients, i.v. atropine should be given. If this fails, pacing should be instituted.
Second-degree Type II (Mobitz II) AV block and complete AV block may be indications for pacing, certainly if bradycardia causes hypotension or heart failure. Revascularization should be considered in non-reperfused patients. AV block associated with inferior infarction is usually supra-Hisian (narrow QRS) and rarely require interventions.
AV block associated with anterior STEMI is usually infraHisian (wide QRS and low escape rhythm), and has a high mortality rate due to the extensive myocardial necrosis. The development of a new BBB or hemiblock usually indicates extensive anterior infarction. A transvenous pacing is indicated in advanced AV block with a low escape rhythm and considered in bifascicular or trifascicular block.
Permanent pacing is indicated in patients with persistent third-degree AV block, persistent second-degree AV block associated with BBB, and transient Mobitz II or complete heart block associated with new onset BBB.
Other cardiac complications
Life threatening mechanical complications may occur especially in patients at advanced age, with Killip II-IV symptoms, 3 vessel disease, anterior wall infarction, prolonged ischaemic time or reduced TIMI flow. At least twice daily clinical examination and echocardiography are needed.
Mitral valve regurgitation
Pathophysiology: LV dilatation, papillary muscle dysfunction or rupture. Symptoms, diagnosis: sudden dyspnoea, pulmonary congestion, new systolic murmur; emergency echocardiography Therapy: intravenous diuretic and vasodilator/inotropic support, IABP, angiography and emergent surgery
LV free wall rupture
Often fatal acute rupture of the LV free wall confirmed by echocardiography may present as sudden pain and electromechanical dissociation. Subacute free wall may permit time for pericardiocentesis and immediate surgery.
Ventricular septal rupture
Symptoms, diagnosis: rapid onset clinical deterioration with acute heart failure and a loud systolic murmur; echocardiography Therapy: IABP, angiography and urgent surgery (no agreement on the optimal timing), intravenous diuretics and vasodilators should be used with caution.
Mortality remains high and is higher in patients with infero-basal defects.
Right ventricular infarction
Pathophysiology: mostly in connection with inferior wall STEMI.
Symptoms: triad of hypotension, clear lung fields and raised jugular venous pressure Diagnosis: elevation of the ST-segment 0.1 mV in V1 and V4R; echocardiography.
Therapy: fluid loading (diuretics and vasodilators should be avoided); maintenance of sinus rhythm
Pericarditis
The incidence has decreased and manifests as recurrent chest pain, usually sharp and related to posture and
respiration. It may be associated with mild and progressive ST-segment re-elevation.
Diagnosis: pericardial rub (often absent due to effusion); echocardiography Therapy: high-dose of aspirin, paracetamol or colchicine (steroids and long-term non-steroidal anti-inflammatory drugs should be avoided); pericardiocentesis, if signs of tamponade.
Anticoagulant therapy should be interrupted unless absolutely indicated.
Left ventricular aneurysm
Pathophysiology: large, especially anterolateral wall STEMI, remodelling, LV dysfunction followed frequently by mitral regurgitation.
Diagnosis: echocardiography (wall-motions, mural thrombus detection).
Therapy: ACE inhibitors/ARBs and aldosterone antagonists early following haemodynamic stabilization; chronic heart failure therapy if needed
Left ventricular thrombus
LV thrombi are associated with poor prognosis but its frequency has decreased during the reperfusion era. Consensus is that mural thrombi, once diagnosed, require oral anticoagulant therapy for up to 6 months (3 months in patients without further thrombi evidence on echocardiography). However, this concept has not been revisited in the era of stenting and DAPT. The bleeding risk during the triple therapy'' is increased and its optimal duration is unknown. r e f e r e n c e s Ã
